Patents Examined by Craig Ricci
  • Pharmaceutical topical composition of mupirocin
    Patent number: 9205149
    Abstract: Anhydrous topical gel composition of mupirocin or its salts comprising: a) a lipophilic base selected from the group consisting of petrolatum, medium-chain triglycerides, isopropyl myristate and mixtures thereof; b) a bioadhesive selected from the group comprising polyvinylpyrrolidone and polymethacrylates; and c) a solvent selected from the group comprising ethanol, propanol, and isopropanol; which is stable and shows an increased residence time of the active ingredient in the skin, resulting in an improved clinical effect in the treatment of bacterial skin infections while maintaining the safety profile of the commercial pharmaceutical product.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: December 8, 2015
    Assignee: LABORATORIOS OJER PHARMA, S.L.
    Inventors: Carlos González Ojer, Beatriz Goñi Allo, Fiona Pastor Fernández, Cayetana Yárnoz De Miguel
  • Pyrido[4,3-B]indoles and methods of use
    Patent number: 9199996
    Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: December 1, 2015
    Assignee: Medivation Technologies, Inc.
    Inventors: Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Methods involving aldose reductase inhibitors
    Patent number: 9198915
    Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: December 1, 2015
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Satish K. Srivastava, Kota V. Ramana
  • Onapristone polymorphic forms and methods of use
    Patent number: 9193757
    Abstract: Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 24, 2015
    Assignee: ARNO THERAPEUTICS, INC.
    Inventor: Stefan Proniuk
  • S1P receptors modulators and their use thereof
    Patent number: 9193716
    Abstract: The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: November 24, 2015
    Assignee: Akaal Pharma PTY LTD.
    Inventors: Gurmit S. Gill, Damian W. Grobelny
  • Zwitterion solution for low-volume therapeutic delivery
    Patent number: 9192672
    Abstract: A formulation is provided that includes a volume of an aqueous multivalent physiological ion solution compatible with cerebrospinal fluid containing at least one divalent cation of magnesium or calcium, and at least one anion of carbonate or phosphate, and having a pH between 6.5 and 8.0. A zwitterionic therapeutic agent other than baclofen is dissolved the solution to achieve higher concentration or ease of solution and/or storage relative to therapeutic saline solutions of the same agent. A process of delivering a zwitterionic therapeutic agent into a subject is provided that includes dissolving a therapeutic amount of the zwitterionic therapeutic agent in a volume of artificial cerebrospinal fluid to form a stable formulation. The solution is then administered to the subject using an intrathecal pump.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: November 24, 2015
    Assignee: Wayne State University Board of Governors
    Inventor: Jay M. Meythaler
  • Water-free cosmetic preparation
    Patent number: 9192557
    Abstract: A water-free composition, in particular a cosmetic composition, in the form of a pencil with a cast or extruded lead or a workable paste which is suitable for cosmetic uses, in particular in the field of decorative cosmetics, for coloring, improving the appearance of and caring for keratinic materials such as for example the skin, semi-mucous membranes and mucous membranes, eyelashes, eyebrows and the hair. That preparation includes a specifically matched combination of water-soluble and lipid-soluble active substances in the form of a so-called “active substance cocktail”. The production and use of that composition are also described.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: November 24, 2015
    Assignee: Schwan-STABILO Cosmetics GmbH & Co. KG
    Inventors: Beatrice Baars, Manfred Bugla, Kerstin Loetzerich-Bernhard
  • Tubulysins and processes for preparing
    Patent number: 9187521
    Abstract: Processes are described for the preparation of tubulysins. The processes are useful for preparing predetermined mixtures of tubulysins, preparing single tubulysins from mixtures of tubulysins, and for converting one tubulysin into a different tubulysin. The tubulysins described herein are useful in treating diseases and disease states that include pathogenic cell populations.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: November 17, 2015
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Yu Wang
  • Methods of treating pains associated with neuroma, nerve entrapment, and other conditions
    Patent number: 9186273
    Abstract: The present disclosure is drawn to methods for treating various types of pain. Specifically, a method for treating various types of pain includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36° C. to 42° C.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: November 17, 2015
    Assignee: Nuvo Research Inc.
    Inventors: Jie Zhang, Robert Lippert
  • Formulations of deoxycholic acid and salts thereof
    Patent number: 9186364
    Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: November 17, 2015
    Assignee: KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Robert Emil Hodge, Jeffrey Douglas Webster
  • Methods involving aldose reductase inhibitors
    Patent number: 9186362
    Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 17, 2015
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Satish K. Srivastava, Kota V. Ramana
  • Medicament for liver regeneration and for treatment of liver failure
    Patent number: 9186381
    Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: November 17, 2015
    Assignees: Helmholtz Zentrum Fuer Infektionsforschung GmbH, Medizinische Hochschule Hannover
    Inventors: Lars Zender, Torsten Wuestefeld
  • Glycerin polysilicones
    Patent number: 9186311
    Abstract: The present invention is directed to a series of glycerin polysilicones. By glycerin polysilicones in meant polymers that have silicone portions that are functionalized with glycerin groups. The polymers of the present invention can range from relatively low molecular weight (around 600 daltons) to higher molecular weight (of about 2,500 daltons). The presence of the glyceryl groups together with the silicone groups allows for the preparation of molecules uniquely suited to personal care applications, more specifically, skin care products.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 17, 2015
    Assignee: Surfa Tech Corporation
    Inventor: Thomas George O'Lenick
  • Aspirin derivatives and uses thereof
    Patent number: 9187402
    Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: November 17, 2015
    Assignee: North Carolina Agricultural and Technical State University
    Inventor: Shengmin Sang
  • Heat assisted lidocaine and tetracaine for transdermal analgesia
    Patent number: 9186334
    Abstract: The present disclosure is drawn to methods for treating various types of pain, including pain associated nerve entrapment, neuroma, headaches, connective tissue, arthritis, injury, and/or overuse. Specifically, the method includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for an application period of at least 30 minutes. Following the application period the analgesic system can be removed and the subject being treated continues to experience reduction of pain for a period of 2 to 10, or even 4 to 12 hours after removal of the analgesic system. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: November 17, 2015
    Assignee: Nuvo Research Inc.
    Inventors: Jie Zhang, Robert Lippert
  • Non-sedating antihistamine injection formulations and methods of use thereof
    Patent number: 9180090
    Abstract: Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: November 10, 2015
    Assignee: JDP THERAPEUTICS, INC.
    Inventor: Jie Du
  • Treatment and inhibition of protozoal diseases with nandrolone and its derivatives
    Patent number: 9173888
    Abstract: This invention provides new therapeutic potential of nandrolone or a derivative thereof, against protozoal diseases. More specifically, nandrolone or a derivative thereof exhibits anti-protozoal activity against Leishmania major. Anti-protozoal potential of nandrolone derivatives, such as compounds 1-8, can contribute in the development of effective therapies against protozoal diseases, such as leishmaniasis, trypanosomiasis, malaria, toxoplasmosis, babeosis, amoebic dysentery and lambliasis. Another aspect of the invention is a method of testing derivatives of nandrolone for anti-protozoal activity comprising growing Leishmania in the presence of the test derivative and determining the IC50 value.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 3, 2015
    Inventors: Elias Baydoun, Muhammad Iqbal Choudhary, Atia-tul- Wahab, Colin Smith, Martin Karam, Dina Farran, Mahwish Shafi Ahmed Khan, Malik Shoaib Ahmad
  • Adamantyl derivatives as therapeutic agents
    Patent number: 9168237
    Abstract: The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 27, 2015
    Assignee: Women & Infants' Hospital of Rhode Island
    Inventors: Richard G. Moore, Rakesh K. Singh
  • Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions
    Patent number: 9162987
    Abstract: Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula (I): wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions comprising a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions, comprising administering a safe and effective amount of a Formula I compound.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: October 20, 2015
    Assignees: University of Louisville Research Foundation, Inc., Advanced Cancer Therapeutics, LLC
    Inventors: Robert A. Mitchell, John O. Trent, Pooran Chand, Gilles Hugues Tapolsky
  • Therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis
    Patent number: 9161925
    Abstract: The present invention relates to the new therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to inhibit apoptosis and treat and/or prevent apoptosis-related diseases and disorders.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: October 20, 2015
    Assignee: SANOFI
    Inventor: Marc Bardou